[go: up one dir, main page]

WO2001013715A3 - Animal model and uses thereof - Google Patents

Animal model and uses thereof Download PDF

Info

Publication number
WO2001013715A3
WO2001013715A3 PCT/GB2000/003274 GB0003274W WO0113715A3 WO 2001013715 A3 WO2001013715 A3 WO 2001013715A3 GB 0003274 W GB0003274 W GB 0003274W WO 0113715 A3 WO0113715 A3 WO 0113715A3
Authority
WO
WIPO (PCT)
Prior art keywords
animal models
animal model
disorders
models
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2000/003274
Other languages
French (fr)
Other versions
WO2001013715A2 (en
Inventor
Piers Christopher Emson
Lawrence Stephen Wilkinson
Katrin Mooslehner-Allen
Weiming Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Babraham Institute
Original Assignee
Babraham Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Babraham Institute filed Critical Babraham Institute
Priority to AU67131/00A priority Critical patent/AU6713100A/en
Publication of WO2001013715A2 publication Critical patent/WO2001013715A2/en
Publication of WO2001013715A3 publication Critical patent/WO2001013715A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Animal models are provided for pathologies involving monoamine dysfunction in which the vesicular monoamine transporter (2) (VMAT2) gene has been manipulated. Such models are useful particularly in study of various disorders, especially Parkinson's disease, schizophrenia and drug dependencies, and in assay methods for obtaining agents of therapeutic potential in such disorders. Assays and methods of generating animal models are also provided.
PCT/GB2000/003274 1999-08-24 2000-08-23 Animal model and uses thereof Ceased WO2001013715A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU67131/00A AU6713100A (en) 1999-08-24 2000-08-23 Animal model and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9920074.3A GB9920074D0 (en) 1999-08-24 1999-08-24 Animal model and uses thereof
GB9920074.3 1999-08-24

Publications (2)

Publication Number Publication Date
WO2001013715A2 WO2001013715A2 (en) 2001-03-01
WO2001013715A3 true WO2001013715A3 (en) 2001-09-20

Family

ID=10859745

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003274 Ceased WO2001013715A2 (en) 1999-08-24 2000-08-23 Animal model and uses thereof

Country Status (3)

Country Link
AU (1) AU6713100A (en)
GB (1) GB9920074D0 (en)
WO (1) WO2001013715A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114317604B (en) * 2022-03-04 2022-06-17 中国医学科学院阜外医院 A Spontaneous Pulmonary Arterial Hypertension Model and Construction Method

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025699A1 (en) * 1992-06-11 1993-12-23 The Regents Of The University Of California Vesicle membrane transport proteins
WO1994026274A1 (en) * 1993-05-18 1994-11-24 Wake Forest University Treatment process with biologically active tropane derivatives
WO1996027009A1 (en) * 1995-03-01 1996-09-06 Human Genome Sciences, Inc. Human amine transporter
WO1997012513A1 (en) * 1995-10-02 1997-04-10 Duke University Dopamine transporter knockout mice

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025699A1 (en) * 1992-06-11 1993-12-23 The Regents Of The University Of California Vesicle membrane transport proteins
WO1994026274A1 (en) * 1993-05-18 1994-11-24 Wake Forest University Treatment process with biologically active tropane derivatives
WO1996027009A1 (en) * 1995-03-01 1996-09-06 Human Genome Sciences, Inc. Human amine transporter
WO1997012513A1 (en) * 1995-10-02 1997-04-10 Duke University Dopamine transporter knockout mice

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
FUMAGALLI F ET AL: "Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice", J. NEUROSCI, vol. 19, no. 7, 1 April 1999 (1999-04-01), pages 2424 - 2431, XP000990171 *
LIU L ET AL: "The molecular cloning and expression of a human synaptic vesicle amine transporter that suppresses MPP+ toxicity", MOLECULAR BRAIN RESEARCH, vol. 25, no. 1-2, 1994, pages 90 - 96, XP000990342 *
TAKAHASHI N ET AL: "Murine vesicular monoamine transporter 2: molecular cloning and genomic structure", BRAIN RES MOL BRAIN RES., vol. 49, no. 1-2, 3 October 1997 (1997-10-03), pages 7 - 14, XP000990339 *
TAKAHASHI N ET AL: "VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 94, no. 18, 2 September 1997 (1997-09-02), pages 9938 - 9943, XP002163447 *
UHL G ET AL: "The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins", FASEB J, vol. 14, no. 15, December 2000 (2000-12-01), pages 2459 - 2465, XP002163448 *
WANG Y ET AL: "Altered responses to stress and antidepressants in heterozygous vesicular monoamine transporter 2 (VMAT2) knockout mice", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 24, no. 1-2, 1998, pages 861, XP000990363 *
WANG Y ET AL: "Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine", NEURON, vol. 19, no. 6, December 1997 (1997-12-01), pages 1285 - 1296, XP000990338 *

Also Published As

Publication number Publication date
AU6713100A (en) 2001-03-19
GB9920074D0 (en) 1999-10-27
WO2001013715A2 (en) 2001-03-01

Similar Documents

Publication Publication Date Title
CY1109151T1 (en) DR4 ACCESSORIES AND THEIR USES
CY2015025I2 (en) METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE
IL159527A0 (en) Human dr4 antibodies and uses thereof
DK1054887T3 (en) Bicyclic pyridine and pyrimidine derivatives as neuropeptide Y receptor antagonists
CY1111863T1 (en) OPTIONS AGAINST DEATH RECEPTOR 4 (DR4) AND THEIR USES
NZ522326A (en) Adenosine A2A receptor antagonists
AU2003206413A8 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
ZA200606834B (en) 1-Aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with Alzheimer's disease
EP1542721A4 (en) MODIFIED "S" ANTIBODIES
IL164839A0 (en) Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas
WO2000070945A3 (en) Fatty acid elongation genes and uses thereof
ITMI20020773A0 (en) DRUGS FOR THE TREATMENT OF ARTHRITIS
SI1553985T1 (en) Biphenyls as imaging agents in alzheimer's disease
AU2003303141A8 (en) Hydroxypropyl amides for the treatment of alzheimer's disease
AU2003238046A1 (en) Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer's disease
WO2001013715A3 (en) Animal model and uses thereof
WO2003076658A3 (en) A susceptibility gene for late-onset idiopathic parkinson's disease
IL175004A0 (en) Quick test for the diagnosis of alzheimer's disease
AU2003236714A8 (en) Diagnosis of alzheimer's disease based on the habeta42:habeta40 ratio
AU2003237172A1 (en) Cell cultures from animal models of alzheimer's disease for screening and testing drug efficacy
SI1639139T1 (en) Methods for the diagnosis and prognosis of alzheimer's disease
AU2002316158A1 (en) Methods and compounds for the diagnosis of inflammatory disease and identification of pharmacological agents
AU2002331051A1 (en) An animal model for parkinson's disease
IS7558A (en) A mixture of NMDA antagonists and acetylcholine esterase inhibitors for the treatment of Alzheimer's disease
AU4536599A (en) Metal-rich silica products from geothermal and synthetic aqueous systems nen wie

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP